scholarly journals The role of ryanodine receptor type 3 in a mouse model of Alzheimer disease

Channels ◽  
2014 ◽  
Vol 8 (3) ◽  
pp. 230-242 ◽  
Author(s):  
Jie Liu ◽  
Charlene Supnet ◽  
Suya Sun ◽  
Hua Zhang ◽  
Levi Good ◽  
...  
Keyword(s):  
Alzheimer Disease ◽  
Mouse Model ◽  
Ryanodine Receptor ◽  
Receptor Type ◽  
Type 3

scholarly journals Protective Role of Cannabinoid Receptor Type 2 in a Mouse Model of Diabetic Nephropathy

Diabetes ◽  
2011 ◽  
Vol 60 (9) ◽  
pp. 2386-2396 ◽  
Author(s):  
F. Barutta ◽  
F. Piscitelli ◽  
S. Pinach ◽  
G. Bruno ◽  
R. Gambino ◽  
...  
Keyword(s):  
Diabetic Nephropathy ◽  
Mouse Model ◽  
Cannabinoid Receptor ◽  
Protective Role ◽  
Receptor Type ◽  
Cannabinoid Receptor Type 2

scholarly journals Up-regulation of the type 3 ryanodine receptor is neuroprotective in the TgCRND8 mouse model of Alzheimer’s disease

2010 ◽  
Vol 112 (2) ◽  
pp. 356-365 ◽  
Author(s):  
Charlene Supnet ◽  
Charmaine Noonan ◽  
Kelly Richard ◽  
John Bradley ◽  
Michael Mayne
Keyword(s):  
Mouse Model ◽  
Ryanodine Receptor ◽  
Tgcrnd8 Mouse ◽  
Type 3

P4-029: The role of the renin-angiotensin system and apolipoprotein e in a sporadic Alzheimer disease mouse model

2015 ◽  
Vol 11 (7S_Part_17) ◽  
pp. P776-P776
Author(s):  
Christopher John De Vera ◽  
Andrew Ho ◽  
Monica Castro ◽  
Carleton B. Jones ◽  
T. Bucky Jones
Keyword(s):  
Alzheimer Disease ◽  
Mouse Model ◽  
Apolipoprotein E ◽  
Renin Angiotensin System ◽  
Angiotensin System ◽  
Renin Angiotensin ◽  
Sporadic Alzheimer Disease

scholarly journals Blockade of CC Chemokine Receptor Type 3 Diminishes Pain and Enhances Opioid Analgesic Potency in a Model of Neuropathic Pain

2021 ◽  
Vol 12 ◽  
Author(s):  
Katarzyna Pawlik ◽  
Agata Ciechanowska ◽  
Katarzyna Ciapała ◽  
Ewelina Rojewska ◽  
Wioletta Makuch ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Neuropathic Pain ◽  
Chemokine Receptor ◽  
Pain Treatment ◽  
Opioid Analgesic ◽  
Receptor Type ◽  
Clinical Issue ◽  
Cc Chemokine ◽  
Type 3

Neuropathic pain is a serious clinical issue, and its treatment remains a challenge in contemporary medicine. Thus, dynamic development in the area of animal and clinical studies has been observed. The mechanisms of neuropathic pain are still not fully understood; therefore, studies investigating these mechanisms are extremely important. However, much evidence indicates that changes in the activation and infiltration of immune cells cause the release of pronociceptive cytokines and contribute to neuropathic pain development and maintenance. Moreover, these changes are associated with low efficacy of opioids used to treat neuropathy. To date, the role of CC chemokine receptor type 3 (CCR3) in nociception has not been studied. Similarly, little is known about its endogenous ligands (C-C motif ligand; CCL), namely, CCL5, CCL7, CCL11, CCL24, CCL26, and CCL28. Our research showed that the development of hypersensitivity in rats following chronic constriction injury (CCI) of the sciatic nerve is associated with upregulation of CCL7 and CCL11 in the spinal cord and dorsal root ganglia (DRG). Moreover, our results provide the first evidence that single and repeated intrathecal administration of the CCR3 antagonist SB328437 diminishes mechanical and thermal hypersensitivity. Additionally, repeated administration enhances the analgesic properties of morphine and buprenorphine following nerve injury. Simultaneously, the injection of SB328437 reduces the protein levels of some pronociceptive cytokines, such as IL-6, CCL7, and CCL11, in parallel with a reduction in the activation and influx of GFAP-, CD4- and MPO-positive cells in the spinal cord and/or DRG. Moreover, we have shown for the first time that an inhibitor of myeloperoxidase-4-aminobenzoic hydrazide may relieve pain and simultaneously enhance morphine and buprenorphine efficacy. The obtained results indicate the important role of CCR3 and its modulation in neuropathic pain treatment and suggest that it represents an interesting target for future investigations.

Ryanodine receptor type 3 (RYR3) as a novel gene associated with nemaline myopathy and fibre type disproportion

2016 ◽  
Vol 26 ◽  
pp. S137 ◽  
Author(s):  
Y. Nilipour ◽  
S. Nafissi ◽  
V. Varasteh ◽  
H. Hossein-Nejad ◽  
S. Tonekaboni ◽  
...  
Keyword(s):  
Ryanodine Receptor ◽  
Fibre Type ◽  
Nemaline Myopathy ◽  
Receptor Type ◽  
Novel Gene ◽  
Type 3
Sign in / Sign up

Export Citation Format

Share Document